Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20135819 | 0.84 | TMPRSS2 (0.40) | TMPRSS2 | |
| SCHEMBL30118449 | 0.83 | TMPRSS2 (0.39) | TMPRSS2 | |
| SCHEMBL30118447 | 0.83 | TMPRSS2 (0.39) | TMPRSS2 | |
| SCHEMBL17712233 | 0.82 | TMPRSS2 (0.39) | TMPRSS2 | |
| SCHEMBL26206204 | 0.81 | TMPRSS2 (0.45) | TMPRSS2 | |
| SCHEMBL23697319 | 0.79 | TMPRSS2 (0.43) | TMPRSS2 | |
| SCHEMBL18636437 | 0.79 | TMPRSS2 (0.43) | TMPRSS2 | |
| SCHEMBL22096270 | 0.78 | TMPRSS2 (0.44) | TMPRSS2 | |
| SCHEMBL23696910 | 0.78 | TMPRSS2 (0.40) | TMPRSS2 | |
| SCHEMBL17712236 | 0.77 | TMPRSS2 (0.39) | TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | EWHA WOMANS UNIVERSITY (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230181582-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH VIRAL INFECTIONS | Qx Therapeutics Inc. (US) | 2023-06-15 | — | — | US | disclosed |
| US-11497747-B2 | Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections | Qx Therapeutics Inc. (US) | 2022-11-15 | — | — | US | disclosed |
| WO-2022118975-A1 | SARS-CoV-2 SPIKE PROTEIN VARIANT AND APPLICATION THEREOF | ＨｕＬＡ ｉｍｍｕｎｅ株式会社 | 2022-06-09 | — | — | WO | disclosed |
| US-11304947-B2 | Compositions and methods for treating lung injuries associated with SARS-COV-2 infections | Qx Therapeutics Inc. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210361650-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH SARS-COV-2 INFECTIONS | Qx Therapeutics Inc. (US) | 2021-11-25 | — | — | US | disclosed |
| US-20210315973-A1 | COMPOSITIONS AND METHODS USING INTERFERON FOR TREATING VIRAL RESPIRATORY INFECTIONS | NOSTRUM PHARMACEUTICALS, LLC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11497747-B2 | Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections | MAP3K3, MAP3K2, MAP3K13 | TMPRSS2 31/4885 |
| US-11304947-B2 | Compositions and methods for treating lung injuries associated with SARS-COV-2 infections | MAP3K3, MAP3K2, MAP3K13 | TMPRSS2 31/4885 |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | ACE2, ACE, TMPRSS2 | TMPRSS2 3/4885 |
| US-20230181582-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH VIRAL INFECTIONS | MAP3K3, MAP3K2, MAP3K21 | TMPRSS2 38/4885 |
| US-20210361650-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH SARS-COV-2 INFECTIONS | MAP3K3, MAP3K2, MAP3K13 | TMPRSS2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.